高级搜索
刘伟玲, 董兵, 郭永军. BRCA突变型乳腺癌的靶向治疗研究进展[J]. 肿瘤防治研究, 2017, 44(1): 75-78. DOI: 10.3971/j.issn.1000-8578.2017.01.016
引用本文: 刘伟玲, 董兵, 郭永军. BRCA突变型乳腺癌的靶向治疗研究进展[J]. 肿瘤防治研究, 2017, 44(1): 75-78. DOI: 10.3971/j.issn.1000-8578.2017.01.016
LIU Weiling, DONG Bing, GUO Yongjun. Review of Targeted Therapy for Breast Cancer with BRCA Genes Mutation[J]. Cancer Research on Prevention and Treatment, 2017, 44(1): 75-78. DOI: 10.3971/j.issn.1000-8578.2017.01.016
Citation: LIU Weiling, DONG Bing, GUO Yongjun. Review of Targeted Therapy for Breast Cancer with BRCA Genes Mutation[J]. Cancer Research on Prevention and Treatment, 2017, 44(1): 75-78. DOI: 10.3971/j.issn.1000-8578.2017.01.016

BRCA突变型乳腺癌的靶向治疗研究进展

Review of Targeted Therapy for Breast Cancer with BRCA Genes Mutation

  • 摘要: 乳腺癌是女性最常见的恶性肿瘤,BRCA1/BRCA2是乳腺癌重要的易感基因,与遗传性乳腺癌的发生密切相关,目前BRCA基因突变型乳腺癌的靶向药物治疗是研究的热点。本文主要介绍BRCA基因在乳腺癌中的发生发展关系,并对其相关靶向治疗作一综述。

     

    Abstract: Breast cancer is the most common cancer in female malignant tumors. BRCA1 and BRCA2 are the important susceptibility genes, and have a close relationship with the incidence of breast cancer. Currently, the targeted drugs of breast cancer with BRCA mutations become a research hotspot. This article is to sum up the connection between BRCA genes and breast cancer, and review on related targeted therapy methods.

     

/

返回文章
返回